Von Hippel-Lindau Disease (VHL)

1. Overview

Von Hippel-Lindau (VHL) disease is an autosomal dominant hereditary cancer syndrome caused by germline mutations in the VHL tumour suppressor gene on chromosome 3p25.3. [1,2] The condition predisposes individuals to the development of multiple highly vascular tumours across various organ systems, most notably central nervous system (CNS) haemangioblastomas, retinal haemangioblastomas, clear cell renal cell carcinomas (ccRCC), phaeochromocytomas, and pancreatic neuroendocrine tumours. [3,4]

The incidence is approximately 1 in 36,000 live births, with a prevalence of 1 in 53,000, making it a rare but clinically significant disorder. [1,5] Disease penetrance exceeds 90% by age 65, with the mean age of diagnosis at 26 years, though clinical manifestations may present from childhood through the sixth decade. [2,6] Approximately 20% of cases arise from de novo mutations, while the remaining 80% are inherited from an affected parent. [1]

VHL disease is the leading cause of hereditary renal cell carcinoma, accounting for ccRCC development in 40-60% of affected individuals, typically presenting as bilateral, multifocal tumours. [7,8] Historically, renal cell carcinoma and CNS haemangioblastoma complications were the primary causes of VHL-related mortality, with median survival previously limited to 49 years. [2] However, the advent of systematic surveillance protocols and novel targeted therapies, particularly the HIF-2α inhibitor belzutifan, has dramatically transformed the natural history and prognosis of this condition. [9,10]

Early diagnosis through genetic testing and adherence to lifelong, multi-organ surveillance protocols are critical for optimal outcomes. The management paradigm emphasizes early detection and nephron-sparing interventions to preserve renal function while minimizing cancer-related morbidity and mortality. [11]

---

2. Epidemiology

Incidence and Prevalence

Demographics and Risk Factors

VHL disease affects all ethnic groups and demonstrates no sex predilection, with equal male-to-female ratios. [1,2] The condition shows complete penetrance in most families, though the age of onset and spectrum of manifestations vary considerably even among members of the same family carrying identical mutations. [6]

Organ-Specific Manifestation Frequencies

---

3. Aetiology and Pathophysiology

Genetic Basis

VHL disease results from germline loss-of-function mutations in the VHL tumour suppressor gene located on chromosome 3p25.3. [1,2] The gene encodes the von Hippel-Lindau protein (pVHL), a 213-amino acid protein that functions as the substrate recognition component of an E3 ubiquitin ligase complex. [13] Following Knudson's "two-hit hypothesis," affected individuals inherit one mutated VHL allele, and tumour development occurs when the second wild-type allele undergoes somatic inactivation. [2]

The VHL-HIF-VEGF Axis: Molecular Pathophysiology

The hallmark molecular defect in VHL disease involves dysregulation of the hypoxia-inducible factor (HIF) pathway, leading to a state of "pseudohypoxia" even under normoxic conditions. [13,14]

Normal Oxygen Sensing:

1. Under normoxic conditions, oxygen-dependent prolyl hydroxylases (EglN/PHD enzymes) hydroxylate specific proline residues (Pro402 and Pro564) on HIF-α subunits (HIF-1α and HIF-2α)
2. Prolyl-hydroxylated HIF-α is recognized by pVHL, which recruits an E3 ubiquitin ligase complex (comprising elongin B, elongin C, cullin-2, and Rbx1)
3. HIF-α undergoes polyubiquitylation and proteasomal degradation
4. HIF-responsive genes remain transcriptionally inactive [13,14]

VHL-Deficient State:

1. Loss of functional pVHL prevents HIF-α recognition and ubiquitylation
2. HIF-α accumulates constitutively, regardless of oxygen availability
3. Stabilized HIF-α dimerizes with HIF-β (ARNT) and translocates to the nucleus
4. The HIF heterodimer binds hypoxia response elements (HREs) in target gene promoters
5. Upregulation of > 100 HIF target genes, including:
   • VEGF (vascular endothelial growth factor) → angiogenesis and vascular tumour formation
   • PDGF (platelet-derived growth factor) → stromal proliferation
   • EPO (erythropoietin) → erythrocytosis/polycythaemia
   • GLUT1 → enhanced glucose uptake (Warburg effect)
   • TGF-α, CXCR4, SDF-1 → proliferation and metastasis [13,14]

HIF-2α as the Primary Oncogenic Driver: Recent evidence demonstrates that HIF-2α, rather than HIF-1α, is the dominant oncogenic driver in VHL-associated ccRCC and CNS haemangioblastomas. [9,14] This discovery led to the development of HIF-2α-selective inhibitors (belzutifan) as targeted therapy. [9]

Genotype-Phenotype Correlations

VHL disease is classified into subtypes based on phaeochromocytoma risk, which correlates with the degree of HIF dysregulation: [2,3]

The spectrum of HIF dysregulation correlates with tumour risk: complete loss of pVHL function (Type 1) causes maximal HIF accumulation and highest risk of haemangioblastomas and RCC, while partial retention of function (Type 2) creates intermediate HIF levels associated with phaeochromocytoma development. [14]

---

4. Clinical Presentation

VHL disease manifests as a multisystem disorder with age-dependent and variable penetrance of individual tumour types. Clinical presentation depends on the location, size, and biological behavior of developing lesions.

CNS Haemangioblastomas (60-80%)

Haemangioblastomas are benign but highly vascular tumours composed of stromal cells and abundant capillary networks. They are the most common CNS manifestation of VHL disease. [3,11]

Anatomical Distribution:

• Cerebellum (60%) > Spinal cord (40%) > Brainstem (15%) > Cerebral hemispheres (less than 5%)
• Often multiple lesions, with new tumours developing over time
• Typically cystic masses with enhancing mural nodules

Clinical Features by Location:

Associated Phenomena:

• Polycythaemia: Ectopic EPO secretion occurs in 10-20% of cerebellar haemangioblastomas, causing haemoglobin > 180 g/L [3,11]
• Haemorrhage: Spontaneous tumour haemorrhage may cause acute neurological deterioration
• Growth pattern: Slow-growing, but unpredictable; some remain stable for years, others demonstrate rapid expansion

Retinal Haemangioblastomas (60-85%)

Retinal angiomas (also called retinal capillary haemangioblastomas) are often the earliest manifestation of VHL disease, presenting in childhood or early adulthood. [3,11]

Clinical Features:

• Location: Peripheral retina (75%) > Juxtapapillary (optic disc region, 25%)
• Appearance: Orange-red, well-circumscribed vascular tumours with dilated tortuous feeder vessels
• Symptoms: Often asymptomatic initially; may cause floaters, decreased visual acuity, metamorphopsia

Complications:

• Exudative retinal detachment (most common cause of vision loss)
• Vitreous haemorrhage
• Epiretinal membrane formation
• Macular oedema
• Secondary glaucoma
• Blindness: Risk in untreated cases due to retinal detachment

Natural History:

• Lesions may be bilateral (50% of cases) and multifocal (30%)
• New tumours develop throughout life, requiring continuous surveillance

Clear Cell Renal Cell Carcinoma (40-70%)

Renal manifestations are the leading cause of mortality in VHL disease and require intensive surveillance. [7,8]

Characteristics:

• Histology: Clear cell RCC (100% of VHL-associated RCC)
• Pattern: Bilateral (75%), multifocal, arising from renal cysts
• Age of onset: Mean 39 years, but can present in 20s-30s
• Associated findings: Multiple renal cysts (50-70% of patients)

Clinical Presentation:

• Often asymptomatic, detected on surveillance imaging
• Symptomatic presentations: haematuria, flank pain, palpable mass (late findings)
• Metastatic disease: weight loss, bone pain, respiratory symptoms (if untreated)

Growth and Metastatic Risk:

• 3 cm threshold: Tumours less than 3 cm have low metastatic potential (less than 2% risk)
• Tumours > 3 cm: Significantly increased metastatic risk (up to 27% for lesions > 3 cm) [8]
• Growth rate highly variable between individual tumours and patients
• Bilateral disease and young age necessitate nephron-sparing approach to prevent dialysis dependency

Phaeochromocytoma and Paraganglioma (10-20%)

These catecholamine-secreting tumours arise from chromaffin cells and are more common in VHL Type 2 families. [3,11]

Clinical Features:

Characteristics:

• Bilateral adrenal involvement in 40-80% (vs less than 10% in sporadic cases)
• Extra-adrenal paragangliomas uncommon but possible
• Generally benign (malignancy less than 5% in VHL, vs 10% sporadic)
• May be clinically silent (detected on biochemical screening)

Complications:

• Hypertensive crisis (triggered by surgery, anaesthesia, trauma, medications)
• Cardiovascular: arrhythmias, myocardial infarction, stroke, cardiomyopathy
• Life-threatening if undiagnosed before surgery or anaesthesia

Pancreatic Manifestations (35-70%)

Pancreatic involvement is highly variable and includes both cystic and neoplastic lesions. [12]

Pancreatic Cysts:

• Simple cysts or serous cystadenomas
• Often multiple, asymptomatic
• No malignant potential
• May cause compression if large

Pancreatic Neuroendocrine Tumours (pNETs):

• Occur in 12-17% of VHL patients [12]
• Usually non-functional (asymptomatic)
• Functional tumours rare: insulinoma, gastrinoma (exceptional)
• Metastatic potential exists, particularly for tumours > 2-3 cm
• Growth rate highly variable

Endolymphatic Sac Tumours (10-15%)

These rare tumours of the inner ear present with audiovestibular symptoms: [3,11]

• Progressive sensorineural hearing loss (most common)
• Tinnitus
• Vertigo
• Facial nerve palsy (if locally invasive)

Bilateral tumours occur in ~30% of affected individuals. Early detection via MRI and surgical intervention can preserve hearing.

Other Manifestations

• Epididymal cystadenomas: Benign, often bilateral, usually asymptomatic; occur in 25-60% of males [3]
• Broad ligament cystadenomas: Female equivalent; rare
• CNS haemangioblastomas in supratentorial locations: Rare but reported

---

5. Differential Diagnosis

Primary Differential Considerations

Rare Inherited Renal Cancer Syndromes

• Hereditary Leiomyomatosis and RCC (HLRCC): Cutaneous/uterine leiomyomas, aggressive papillary type 2 RCC (FH mutations)
• Birt-Hogg-Dubé Syndrome: Skin fibrofolliculomas, pulmonary cysts, chromophobe/oncocytic renal tumours (FLCN mutations)
• Hereditary Papillary RCC: Multiple bilateral papillary type 1 RCC (MET mutations)

---

6. Investigations

Genetic Testing

Diagnostic Genetic Testing:

• Indication: Clinical diagnosis of VHL disease or high suspicion based on manifestations
• Method: Full gene sequencing and deletion/duplication analysis of VHL gene
• Sensitivity: ~100% detection rate for pathogenic germline mutations [1,2]
• Results interpretation: Pathogenic variants confirm diagnosis; variant of uncertain significance (VUS) requires expert genetic counselling

Predictive Genetic Testing:

• Indication: At-risk first-degree relatives of confirmed VHL patients
• Timing: Can be performed from birth; surveillance initiated based on results
• Genetic counselling: Mandatory pre- and post-test counselling regarding implications, surveillance burden, reproductive options

Prenatal and Preimplantation Genetic Diagnosis:

• Available for families with known pathogenic VHL mutations
• Preimplantation genetic testing (PGT) allows selection of unaffected embryos during IVF

Surveillance Imaging and Biochemistry

Lifelong, multi-organ surveillance is the cornerstone of VHL disease management. International consensus guidelines (2023) provide evidence-based recommendations. [11]

Surveillance Protocol Summary

Detailed Imaging Characteristics

CNS Haemangioblastomas (MRI):

• T1: Hypointense cyst with isointense mural nodule
• T2: Hyperintense cyst; variable nodule signal
• Contrast enhancement: Intense homogeneous enhancement of mural nodule and prominent flow voids (feeding vessels)
• Associated findings: Syringomyelia (spinal cord), peritumoral oedema

Renal Cell Carcinoma (MRI/CT):

• Appearance: Solid enhancing masses; may be partially cystic
• Pattern: Bilateral, multifocal lesions of varying sizes
• Cysts: Multiple simple and complex cysts
• Enhancement: Moderate to marked enhancement (> 20 HU on CT, heterogeneous on MRI)

Phaeochromocytoma (MRI):

• T2-weighted: Classic "light bulb" sign (very high signal intensity)
• T1-weighted: Intermediate signal intensity
• Contrast: Avid enhancement
• Functional imaging: MIBG scintigraphy, ⁶⁸Ga-DOTATATE PET/CT (if extra-adrenal suspected)

Biochemical Investigations

Screening for Phaeochromocytoma:

• Plasma free metanephrines and normetanephrines: Most sensitive (96-100%) and specific (85-89%) [11]
• 24-hour urine fractionated metanephrines: Alternative if plasma testing unavailable
• Interpretation: Elevations > 2-3× upper limit of normal highly suggestive

Polycythaemia Evaluation:

• Full blood count: Haemoglobin > 180 g/L in males, > 165 g/L in females
• Serum EPO: Elevated in haemangioblastoma-associated polycythaemia
• Consider: JAK2 mutation analysis to exclude polycythaemia vera if no haemangioblastoma identified

Pancreatic NET Markers (if pNET suspected):

• Chromogranin A (may be elevated but non-specific)
• Functional hormone assays only if clinical symptoms suggest functional tumour

---

7. Classification and Staging

VHL Disease Classification (Genotype-Phenotype)

As detailed in Section 3, VHL disease is classified into types based on phaeochromocytoma risk and underlying mutation type:

• Type 1: Low phaeochromocytoma risk; high RCC and haemangioblastoma risk
• Type 2A: High phaeochromocytoma and haemangioblastoma risk; low RCC risk
• Type 2B: High phaeochromocytoma, haemangioblastoma, and RCC risk
• Type 2C: Phaeochromocytoma only (isolated)

Genotype-phenotype correlations have clinical significance for surveillance planning and risk stratification. [2,3,23]

Renal Cell Carcinoma Staging (TNM 8th Edition)

VHL-associated RCC is staged using the standard TNM system, though the multifocal and bilateral nature complicates staging.

Note: In VHL patients with bilateral multifocal disease, the largest or most aggressive tumour determines staging.

---

8. Management

Management of VHL disease requires multidisciplinary coordination involving genetics, ophthalmology, neurosurgery, urology, endocrinology, medical oncology, and radiology. The overarching principles are:

1. Surveillance-first approach: Detect lesions early when intervention is most effective
2. Nephron preservation: Avoid total nephrectomy to prevent dialysis dependency
3. Functional preservation: Timely intervention for sight-threatening, neurologically compromising, or life-threatening lesions
4. Targeted systemic therapy: Belzutifan for progressive multifocal disease

CNS Haemangioblastomas

Indications for Intervention:

• Symptomatic tumours (headache, neurological deficit, ataxia)
• Tumours causing or at risk of causing hydrocephalus
• Progressive tumour growth on surveillance imaging
• Associated syringomyelia with clinical symptoms

Treatment Options:

Surgical Considerations:

• Gross total resection of mural nodule (cyst wall left in situ) is curative for individual tumours
• Preoperative embolization may reduce intraoperative bleeding for highly vascular lesions
• Spinal cord haemangioblastomas: high morbidity risk; careful patient selection essential
• Cerebellar haemangioblastomas: 98% symptom improvement/stabilization 3 months post-resection; no recurrence with meticulous extracapsular resection [22]
• Posterior cerebellum (74%) more commonly affected than anterior (26%) [22]

Retinal Haemangioblastomas

Treatment Indications:

• All retinal angiomas warrant treatment to prevent vision-threatening complications
• Early intervention when tumours are small yields best visual outcomes

Treatment Modalities:

Prognosis:

• Early detection and treatment maintain vision in > 90% of patients [11]
• Delayed treatment risks irreversible vision loss from retinal detachment
• Belzutifan demonstrates 100% response rate (all 16 eyes improved) in LITESPARK-004 ocular subgroup analysis, with sustained effects greater than 2 years [21]

Renal Cell Carcinoma: The 3 cm Rule and Nephron-Sparing Surgery

VHL patients face lifelong risk of developing new renal tumours. The "3 cm rule" balances oncological control with renal preservation. [8]

Management Algorithm:

      RCC detected on surveillance MRI
                    ↓
         Measure largest diameter
                    ↓
    ┌───────────────┴───────────────┐
   less than 3 cm                          ≥3 cm
    ↓                                ↓
Surveillance                  Intervention indicated
(repeat MRI 6-12 months)            ↓
    ↓                         ┌──────┴───────┐
If growth:                    Surgery      Ablation
→ Continue surveillance    (preferred)    (selected cases)
   until ≥3 cm                  ↓              ↓
    OR rapid growth     Partial nephrectomy   RFA/Cryoablation
                        (nephron-sparing)

Surgical Management:

Partial Nephrectomy (Nephron-Sparing Surgery):

• Technique: Tumour enucleation or wedge resection with minimal healthy parenchyma removal
• Approach: Open, laparoscopic, or robotic-assisted
• Warm ischaemia time: less than 20-25 minutes to minimize ischaemic injury
• Outcomes: Preserves renal function; recurrence-free survival 80-90% at 5 years [8,24]
• Repeat surgery: VHL patients often undergo multiple partial nephrectomies over lifetime
• Metastatic risk by size: No metastases in tumours less than 3 cm; significantly increased risk for tumours ≥3 cm [8,24]

Thermal Ablation (Radiofrequency/Cryoablation):

• Indications: Small (less than 3 cm), peripherally located tumours; poor surgical candidates
• Technique: Percutaneous or laparoscopic probe insertion; thermal destruction
• Outcomes: Local recurrence rates higher than surgery (5-15%) but acceptable for selected cases

Radical Nephrectomy:

• Indication: Only when nephron-sparing approaches not feasible; avoided whenever possible due to risk of dialysis dependency with bilateral disease

Systemic Therapy (Belzutifan):

• Indicated for patients with multiple progressive renal tumours when repeated surgery would compromise renal function
• Detailed below in Section 8.5

Phaeochromocytoma Management

Preoperative Preparation (Essential): Phaeochromocytoma resection without adequate α-blockade can precipitate life-threatening hypertensive crisis, arrhythmias, or cardiovascular collapse.

Medical Preparation (14-21 days preoperatively):

1. α-adrenergic blockade:
   • Phenoxybenzamine 10-20 mg BD, titrate to BP control (target BP less than 130/80 mmHg, standing BP > 90 mmHg)
   • Alternative: Doxazosin 2-8 mg daily
2. β-adrenergic blockade (ONLY after α-blockade established):
   • Propranolol 20-40 mg TDS or atenolol 25-50 mg daily
   • Never initiate β-blockade before α-blockade (risk of unopposed α-agonism → severe hypertension)
3. Volume expansion: High-salt diet, IV fluids day before surgery

Surgical Approach:

• Laparoscopic adrenalectomy: Preferred approach; minimal morbidity
• Open adrenalectomy: Reserved for large tumours or suspicion of malignancy
• Bilateral disease: Consider cortical-sparing adrenalectomy if feasible to avoid adrenal insufficiency

Postoperative Care:

• Monitor for hypotension (loss of catecholamine stimulus)
• If bilateral adrenalectomy: lifelong glucocorticoid and mineralocorticoid replacement

Pancreatic Neuroendocrine Tumours (pNETs)

Management Strategy:

Surgical Options:

• Enucleation (for small, superficial tumours)
• Distal pancreatectomy
• Pancreaticoduodenectomy (Whipple procedure) for head lesions (rare in VHL)

Systemic Therapy:

• Somatostatin analogues (octreotide, lanreotide) for unresectable or metastatic pNETs
• Belzutifan: emerging evidence for efficacy in VHL-associated pNETs [10]

Belzutifan: Targeted HIF-2α Inhibition (Game Changer)

Belzutifan is an oral, selective HIF-2α inhibitor approved by the FDA (2021) and EMA (2023) for VHL disease-associated RCC, CNS haemangioblastomas, and pNETs requiring therapy but not immediate surgery. [9,10]

Mechanism of Action:

• Allosteric inhibitor that binds to HIF-2α, preventing dimerization with ARNT
• Blocks HIF-2α transcriptional activity and downstream VEGF/EPO production [9]

LITESPARK-004 Phase 2 Trial Results: [9,10,19,20]

Indications:

• VHL patients with progressive RCC, CNS haemangioblastomas, or pNETs not requiring immediate surgery
• Patients facing renal insufficiency from repeated surgeries
• Patients with multiple, unresectable tumours

Dosing:

• 120 mg orally once daily (continuously)

Adverse Effects:

Duration of Therapy:

• Indefinite (tumour regrowth occurs upon cessation)
• Treatment interruptions may be needed for surgery or severe toxicity

Clinical Impact: Belzutifan has fundamentally altered VHL management by providing a medical alternative to repeated surgeries, allowing many patients to defer or avoid nephrectomy, craniotomy, or spinal surgery. [9,10]

---

9. Complications

Disease-Related Complications

Treatment-Related Complications

Surgical Complications:

• Partial nephrectomy: bleeding, urine leak, renal insufficiency, need for total nephrectomy (~5% risk)
• CNS haemangioblastoma resection: neurological deficit (5-15%), CSF leak, infection
• Adrenalectomy: adrenal insufficiency (if bilateral), bleeding, infection

Belzutifan Toxicity:

• Anaemia (may require transfusion or EPO in severe cases)
• Hypoxia (exacerbated at altitude; patients advised to avoid high-altitude travel)

---

10. Prognosis

Historical vs Contemporary Outcomes

Prognostic Factors

Favorable:

• Early genetic diagnosis and surveillance initiation
• Adherence to surveillance protocols
• Access to multidisciplinary VHL centers
• Type 1 or 2A genotype (lower RCC risk than Type 2B)

Unfavorable:

• Late diagnosis (presenting with metastatic RCC or large haemangioblastomas)
• Poor adherence to surveillance
• Type 2B genotype (high RCC risk)

Organ-Specific Outcomes

Renal Cell Carcinoma:

• 5-year overall survival with surveillance and nephron-sparing approach: 85-95% [8]
• Metastatic disease (if tumours > 3 cm untreated): 5-year survival 20-30%

CNS Haemangioblastomas:

• Gross total resection: cure of individual tumour; risk of new tumours persists
• Morbidity from surgical complications: 5-15%
• Belzutifan: 44-76% objective response rate depending on assessment criteria (solid lesions vs all lesions); sustained benefit greater than 3 years [20,25]

Retinal Haemangioblastomas:

• Visual preservation with early treatment: > 90% [11]

---

11. Prevention and Screening

Primary Prevention

No interventions prevent tumour development in individuals with germline VHL mutations. Reproductive options for affected individuals include:

• Preimplantation genetic testing (PGT) to select unaffected embryos
• Prenatal diagnosis with option for pregnancy termination (ethically complex given treatability of VHL)

Surveillance Screening (Secondary Prevention)

Lifelong, multi-organ surveillance is the standard of care for all individuals with confirmed VHL mutations, as outlined in Section 6. Early detection allows intervention before complications (metastasis, blindness, paralysis) occur.

At-Risk Family Members:

• First-degree relatives should undergo predictive genetic testing
• If positive: enter surveillance protocol
• If negative (true negative, not VUS): discharge from surveillance

---

12. Key Guidelines

International VHL Surveillance Consensus Guidelines (2023)

Published by the International VHL Surveillance Guidelines Consortium, these evidence-based recommendations provide comprehensive surveillance protocols for all VHL-associated manifestations. [11]

Key Recommendations:

• Annual MRI brain/spine starting age 10-15 (earlier if symptomatic)
• Annual dilated ophthalmoscopy from age 1-5
• Annual abdominal MRI from age 16 (kidneys, pancreas, adrenals)
• Annual plasma metanephrines from age 5 (Type 2) or age 16 (Type 1)
• Audiometry and inner ear MRI every 2-3 years from adolescence

NCCN Guidelines: Kidney Cancer (VHL-Associated RCC)

Key Recommendations:

• Active surveillance for RCC less than 3 cm
• Nephron-sparing surgery (partial nephrectomy) for tumours ≥3 cm
• Belzutifan for progressive disease threatening renal function or unresectable tumours

EAU Guidelines on Renal Cell Carcinoma (2023)

VHL-Specific Recommendations:

• Delayed intervention approach (3 cm threshold) to maximize renal preservation
• Avoid radical nephrectomy whenever feasible
• Thermal ablation acceptable for small peripheral tumours

---

13. Common Exam Questions

MRCP/Oncology/Genetics Written Examinations

1. What is the genetic defect in VHL disease?

• Germline loss-of-function mutation in the VHL tumour suppressor gene on chromosome 3p25.3

2. Describe the VHL-HIF-VEGF molecular pathway.

• pVHL normally ubiquitylates hydroxylated HIF-α for proteasomal degradation. Loss of pVHL causes constitutive HIF-α stabilization, leading to VEGF/EPO/PDGF upregulation and pseudohypoxia.

3. What is the 3 cm rule in VHL-associated RCC management?

• RCC less than 3 cm are observed with surveillance imaging; tumours ≥3 cm warrant nephron-sparing surgery due to increased metastatic risk.

4. What is the mechanism of action of belzutifan?

• Belzutifan is an allosteric HIF-2α inhibitor that prevents HIF-2α dimerization with ARNT, blocking transcription of HIF-responsive genes.

5. Why must α-blockade precede β-blockade in phaeochromocytoma preparation?

• Initiating β-blockade first causes unopposed α-adrenergic stimulation, leading to severe hypertension and potential cardiovascular crisis.

6. What causes polycythaemia in VHL disease?

• Ectopic EPO secretion by CNS haemangioblastomas due to constitutive HIF activation.

7. What is the most common cause of blindness in VHL if untreated?

• Exudative retinal detachment from untreated retinal haemangioblastomas.

8. What are the VHL disease subtypes and their phaeochromocytoma risk?

• Type 1: Low phaeochromocytoma risk. Type 2A/2B/2C: High phaeochromocytoma risk. Type 2C is isolated phaeochromocytoma.

---

14. Viva Voce and OSCE Scenarios

Opening Statement for Viva

"Von Hippel-Lindau disease is an autosomal dominant hereditary cancer syndrome caused by germline mutations in the VHL tumour suppressor gene on chromosome 3p25.3, with an incidence of 1 in 36,000 live births. It is characterized by the development of highly vascular tumours including CNS and retinal haemangioblastomas, clear cell renal cell carcinoma, phaeochromocytomas, and pancreatic neuroendocrine tumours. The molecular defect involves dysregulation of the hypoxia-inducible factor pathway, leading to a state of pseudohypoxia and excessive VEGF-driven angiogenesis. Management centers on lifelong multi-organ surveillance, nephron-sparing surgical interventions, and the HIF-2α inhibitor belzutifan, which has revolutionized treatment by providing a non-surgical therapeutic option."

Structured Viva Answer: Managing a VHL Patient with Bilateral RCC

Q: A 35-year-old woman with known VHL disease presents with bilateral renal masses measuring 2.8 cm and 3.5 cm on surveillance MRI. How would you manage her?

A: "I would approach this systematically:

1. Assessment:

• Review imaging to confirm bilateral, multifocal RCC (typical for VHL)
• Assess renal function (creatinine, eGFR)
• Determine previous renal interventions and remaining nephron mass
• Confirm absence of metastatic disease (chest CT)

2. Tumour-Specific Management:

• The 2.8 cm tumour: continue active surveillance (below 3 cm threshold)
• The 3.5 cm tumour: proceed to intervention due to increased metastatic risk

3. Surgical Planning:

• Partial nephrectomy (nephron-sparing approach) for the 3.5 cm tumour
• Approach: robotic-assisted or open, depending on tumour location and complexity
• Goal: gross total resection with maximal preservation of healthy parenchyma
• Warm ischaemia time less than 20 minutes to minimize ischaemic injury

4. Alternative Options:

• Thermal ablation (RFA/cryoablation): if tumour peripherally located and patient high surgical risk
• Belzutifan: if patient refuses surgery, has poor renal reserve, or multiple progressive tumours

5. Long-term Plan:

• Resume surveillance MRI every 6-12 months post-intervention
• Monitor 2.8 cm tumour and assess for new lesions
• Anticipate potential future interventions as new tumours develop
• Consider belzutifan if recurrent surgeries threaten renal function

6. Multidisciplinary Input:

• Urological oncology for surgery
• Medical oncology for consideration of belzutifan
• Genetics for family counselling

The key principle is balancing cancer control with renal preservation to avoid dialysis dependency in this young patient with lifelong risk of new renal tumours."

Common Mistakes in Viva/OSCE

❌ Mistakes that fail candidates:

• Recommending radical nephrectomy for bilateral RCC (destroys remaining renal function)
• Operating on all renal tumours regardless of size (violates 3 cm rule; accelerates renal failure)
• Failing to recognize phaeochromocytoma risk and omitting biochemical screening
• Starting β-blockade before α-blockade in phaeochromocytoma management
• Not appreciating the need for lifelong surveillance and multidisciplinary care

---

15. Patient Explanation (Layperson Level)

What is VHL Disease?

Von Hippel-Lindau disease is an inherited condition that runs in families. It occurs because of a change (mutation) in a gene that normally prevents certain tumours from growing. When this gene doesn't work properly, your body's "oxygen sensor" gets stuck in the "ON" position. This makes your body think it's not getting enough oxygen, even though it is. As a result, your body makes too many blood vessels, which leads to the growth of abnormal, blood vessel-rich tumours in different parts of your body.

Where Can These Tumours Grow?

The tumours commonly develop in:

• Brain and spinal cord: These tumours (called haemangioblastomas) can cause headaches, dizziness, or problems with balance and coordination.
• Eyes: Tumours in the back of your eye can affect your vision if not treated early.
• Kidneys: Kidney cancer (renal cell carcinoma) can develop, but it grows slowly in VHL and is very treatable if caught early.
• Adrenal glands: These small glands sit on top of your kidneys and can develop tumours (phaeochromocytomas) that produce adrenaline, causing high blood pressure, palpitations, and sweating.
• Pancreas: Tumours here are usually harmless but need monitoring.

How is VHL Managed?

The most important part of managing VHL is regular monitoring (surveillance). You will need scans and eye exams every year to catch tumours when they are small and easier to treat. This approach has dramatically improved outcomes—most people with VHL can now live normal lifespans if they stick to their monitoring schedule.

Treatment depends on what develops:

• Eye tumours: Treated with laser to prevent vision loss.
• Kidney tumours: Small tumours are watched. When they reach about 3 cm in size, surgery removes the tumour while saving as much healthy kidney as possible. A newer medicine called belzutifan can also shrink these tumours without surgery.
• Brain and spinal cord tumours: Treated with surgery or, in some cases, medication.
• Adrenal tumours: Require medications to prepare for surgery.

Will I Need Multiple Surgeries?

Possibly. Because VHL causes new tumours to develop over time, some people need more than one surgery during their lifetime. However, the newer medication (belzutifan) can help avoid repeated surgeries for many patients.

Can I Pass This to My Children?

Yes, VHL is inherited. Each of your children has a 50% chance of inheriting the changed gene. Genetic testing can determine if your children carry the mutation, and if they do, they can start surveillance early. For couples planning a family, there are options such as IVF with genetic testing of embryos to ensure unaffected children.

What If I Don't Stick to the Surveillance Schedule?

Skipping scans is dangerous. Without regular monitoring, tumours can grow large before causing symptoms, which can lead to kidney cancer spreading, vision loss, or dangerous complications from brain tumours. The key to living well with VHL is being the CEO of your own health—sticking to your surveillance appointments every year.

---

16. References

1. Maher ER, Neumann HPH, Richard S. Von Hippel-Lindau disease: a clinical and scientific review. Eur J Hum Genet. 2011;19(6):617-623. doi:10.1038/ejhg.2010.175

2. Lonser RR, Glenn GM, Walther M, et al. von Hippel-Lindau disease. Lancet. 2003;361(9374):2059-2067. doi:10.1016/S0140-6736(03)13643-4

3. Chittiboina P, Lonser RR. Von Hippel-Lindau disease. Handb Clin Neurol. 2015;132:139-156. doi:10.1016/B978-0-444-62702-5.00010-X

4. Nielsen SM, Rhodes L, Blanco I, et al. Von Hippel-Lindau disease: genetics and role of genetic counseling in a multiple neoplasia syndrome. J Clin Oncol. 2016;34(18):2172-2181. doi:10.1200/JCO.2015.65.6140

5. Gossage L, Eisen T, Maher ER. VHL, the story of a tumour suppressor gene. Nat Rev Cancer. 2015;15(1):55-64. doi:10.1038/nrc3844

6. Neumann HPH, Wiestler OD. Clustering of features of von Hippel-Lindau syndrome: evidence for a complex genetic locus. Lancet. 1991;337(8749):1052-1054. doi:10.1016/0140-6736(91)91705-y

7. Walther MM, Choyke PL, Glenn G, et al. Renal cancer in families with hereditary renal cancer: prospective analysis of a tumor size threshold for renal parenchymal sparing surgery. J Urol. 1999;161(5):1475-1479. doi:10.1016/S0022-5347(05)68930-6

8. Duffey BG, Choyke PL, Glenn G, et al. The relationship between renal tumor size and metastases in patients with von Hippel-Lindau disease. J Urol. 2004;172(1):63-65. doi:10.1097/01.ju.0000132127.79974.3f

9. Jonasch E, Donskov F, Iliopoulos O, et al. Belzutifan for renal cell carcinoma in von Hippel-Lindau disease. N Engl J Med. 2021;385(22):2036-2046. doi:10.1056/NEJMoa2103425

10. Else T, Jonasch E, Iliopoulos O, et al. Belzutifan for von Hippel-Lindau disease: pancreatic lesion population of the phase 2 LITESPARK-004 study. Clin Cancer Res. 2024;30(9):1750-1757. doi:10.1158/1078-0432.CCR-23-2592

11. Daniels AB, Tirosh A, Huntoon K, et al. Guidelines for surveillance of patients with von Hippel-Lindau disease: consensus statement of the International VHL Surveillance Guidelines Consortium and VHL Alliance. Cancer. 2023;129(19):2927-2940. doi:10.1002/cncr.34896

12. Tirosh A, Sadowski SM, Linehan WM, et al. Association of VHL genotype with pancreatic neuroendocrine tumor phenotype in patients with von Hippel-Lindau disease. JAMA Oncol. 2018;4(1):124-126. doi:10.1001/jamaoncol.2017.3428

13. Kaelin WG Jr. Von Hippel-Lindau disease: insights into oxygen sensing, protein degradation, and cancer. J Clin Invest. 2022;132(18):e162480. doi:10.1172/JCI162480

14. Keith B, Johnson RS, Simon MC. HIF1α and HIF2α: sibling rivalry in hypoxic tumour growth and progression. Nat Rev Cancer. 2011;12(1):9-22. doi:10.1038/nrc3183

15. Shanbhogue KP, Hoch M, Fatterpaker G, Chandarana H. von Hippel-Lindau disease: review of genetics and imaging. Radiol Clin North Am. 2016;54(3):409-422. doi:10.1016/j.rcl.2015.12.004

16. Curry L, Soleimani M. Belzutifan: a novel therapeutic for the management of von Hippel-Lindau disease and beyond. Future Oncol. 2024;20(18):1251-1266. doi:10.2217/fon-2023-0679

17. Palavani LB, Camerotte R, Vieira Nogueira B, et al. Innovative solutions? Belzutifan therapy for hemangioblastomas in Von Hippel-Lindau disease: a systematic review and single-arm meta-analysis. J Clin Neurosci. 2024;128:110774. doi:10.1016/j.jocn.2024.110774

18. Linehan WM, Lerman MI, Zbar B. Identification of the von Hippel-Lindau (VHL) gene: its role in renal cancer. JAMA. 1995;273(7):564-570. doi:10.1001/jama.273.7.564

19. Srinivasan R, Iliopoulos O, Beckermann KE, et al. Belzutifan for von Hippel-Lindau disease-associated renal cell carcinoma and other neoplasms (LITESPARK-004): 50 months follow-up from a single-arm, phase 2 study. Lancet Oncol. 2025;26(5):571-582. doi:10.1016/S1470-2045(25)00099-3

20. Iliopoulos O, Iversen AB, Narayan V, et al. Belzutifan for patients with von Hippel-Lindau disease-associated CNS haemangioblastomas (LITESPARK-004): a multicentre, single-arm, phase 2 study. Lancet Oncol. 2024;25(10):1325-1336. doi:10.1016/S1470-2045(24)00389-9

21. Wiley HE, Srinivasan R, Maranchie JK, et al. Oral hypoxia-inducible factor 2α inhibitor belzutifan in ocular von Hippel-Lindau disease: subgroup analysis of the single-arm phase 2 LITESPARK-004 study. Ophthalmology. 2024;131(11):1324-1332. doi:10.1016/j.ophtha.2024.05.024

22. Jagannathan J, Lonser RR, Smith R, DeVroom HL, Oldfield EH. Surgical management of cerebellar hemangioblastomas in patients with von Hippel-Lindau disease. J Neurosurg. 2008;108(2):210-222. doi:10.3171/JNS/2008/108/2/0210

23. Lonser RR, Weil RJ, Wanebo JE, DeVroom HL, Oldfield EH. Surgical management of spinal cord hemangioblastomas in patients with von Hippel-Lindau disease. J Neurosurg. 2003;98(1):106-116. doi:10.3171/jns.2003.98.1.0106

24. Duffey BG, Choyke PL, Glenn G, et al. The relationship between renal tumor size and metastases in patients with von Hippel-Lindau disease. J Urol. 2004;172(1):63-65. doi:10.1097/01.ju.0000132127.79974.3f

25. Zamarud A, Marianayagam NJ, Park DJ, et al. The outcome of central nervous system hemangioblastomas in Von Hippel-Lindau (VHL) disease treated with belzutifan: a single-institution retrospective experience. J Neurooncol. 2023;165(2):373-379. doi:10.1007/s11060-023-04496-z

26. Neumann HPH, Wiestler OD. Clustering of features of von Hippel-Lindau syndrome: evidence for a complex genetic locus. Lancet. 1991;337(8749):1052-1054. doi:10.1016/0140-6736(91)91705-y

27. Walther MM, Choyke PL, Glenn G, et al. Renal cancer in families with hereditary renal cancer: prospective analysis of a tumor size threshold for renal parenchymal sparing surgery. J Urol. 1999;161(5):1475-1479. doi:10.1016/S0022-5347(05)68930-6

28. Shanbhogue KP, Hoch M, Fatterpaker G, Chandarana H. von Hippel-Lindau disease: review of genetics and imaging. Radiol Clin North Am. 2016;54(3):409-422. doi:10.1016/j.rcl.2015.12.004

29. Curry L, Soleimani M. Belzutifan: a novel therapeutic for the management of von Hippel-Lindau disease and beyond. Future Oncol. 2024;20(18):1251-1266. doi:10.2217/fon-2023-0679

30. Palavani LB, Camerotte R, Vieira Nogueira B, et al. Innovative solutions? Belzutifan therapy for hemangioblastomas in Von Hippel-Lindau disease: a systematic review and single-arm meta-analysis. J Clin Neurosci. 2024;128:110774. doi:10.1016/j.jocn.2024.110774

31. Wanebo JE, Lonser RR, Glenn GM, Oldfield EH. The natural history of hemangioblastomas of the central nervous system in patients with von Hippel-Lindau disease. J Neurosurg. 2003;98(1):82-94. doi:10.3171/jns.2003.98.1.0082

32. Klingler JH, Gläsker S, Bausch B, et al. Hemangioblastoma and von Hippel-Lindau disease: genetic background, spectrum of disease, and neurosurgical treatment. Childs Nerv Syst. 2020;36(10):2537-2552. doi:10.1007/s00381-020-04712-5

33. Ordookhanian C, Kaloostian PE, Ghostine SS, Spiess PE, Etame AB. Management strategies and outcomes for VHL-related craniospinal hemangioblastomas. J Kidney Cancer VHL. 2017;4(3):37-44. doi:10.15586/jkcvhl.2017.90

34. Kim TY, Yoon DH, Shin HC, et al. Spinal cord hemangioblastomas in von Hippel-Lindau disease: management of asymptomatic and symptomatic tumors. Yonsei Med J. 2012;53(6):1073-1080. doi:10.3349/ymj.2012.53.6.1073

35. Jonasch E, Donskov F, Iliopoulos O, et al. Phase III LITESPARK-005 trial: belzutifan versus everolimus in advanced renal cell carcinoma. Future Oncol. 2024;20(1):15-25. doi:10.2217/fon-2023-0532

---

Medical Disclaimer: MedVellum content is for educational purposes and clinical reference. Clinical decisions should account for individual patient circumstances. Always consult appropriate specialists and adhere to local guidelines and protocols.